These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21672248)

  • 1. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
    Prosperi MC; Di Giambenedetto S; Fanti I; Meini G; Bruzzone B; Callegaro A; Penco G; Bagnarelli P; Micheli V; Paolini E; Di Biagio A; Ghisetti V; Di Pietro M; Zazzi M; De Luca A;
    BMC Med Inform Decis Mak; 2011 Jun; 11():40. PubMed ID: 21672248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
    Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
    BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.
    Napravnik S; Eron JJ; Sterling TR; Juday T; Uy J; Moore RD
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):574-80. PubMed ID: 23072322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.
    Wamalwa DC; Lehman DA; Benki-Nugent S; Gasper MA; Gichohi R; Maleche-Obimbo E; Farquhar C; John-Stewart GC; Overbaugh J
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):267-74. PubMed ID: 23196827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
    Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
    HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.
    Bisson GP; Gross R; Bellamy S; Chittams J; Hislop M; Regensberg L; Frank I; Maartens G; Nachega JB
    PLoS Med; 2008 May; 5(5):e109. PubMed ID: 18494555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.
    Deeks SG; Gange SJ; Kitahata MM; Saag MS; Justice AC; Hogg RS; Eron JJ; Brooks JT; Rourke SB; Gill MJ; Bosch RJ; Benson CA; Collier AC; Martin JN; Klein MB; Jacobson LP; Rodriguez B; Sterling TR; Kirk GD; Napravnik S; Rachlis AR; Calzavara LM; Horberg MA; Silverberg MJ; Gebo KA; Kushel MB; Goedert JJ; McKaig RG; Moore RD
    Clin Infect Dis; 2009 Nov; 49(10):1582-90. PubMed ID: 19845473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
    Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.
    Grennan JT; Loutfy MR; Su D; Harrigan PR; Cooper C; Klein M; Machouf N; Montaner JS; Rourke S; Tsoukas C; Hogg B; Raboud J;
    J Infect Dis; 2012 Apr; 205(8):1230-8. PubMed ID: 22438396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
    Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
    BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.